OBJECTIVES: Arginine is a nonessential amino acid which can regulate tumor growth. Argininosuccinate synthetase (ASS) is the rate-limiting enzyme for de novo arginine production. The expression pattern of ASS and the feasibility of arginine deprivation therapy in head and neck cancer have not been investigated. MATERIALS AND METHODS: The growth-inhibitory effect of arginine deprivation therapy was assessed either by proliferation assay with head and neck cancer cells cultured in arginine-free medium, or by tetrazolium/formazan dye assay with cells treated with an arginine-depleting drug (arginine deiminase, ADI). The tumor ASS status of 73 oral squamous carcinoma (OSCC) patients was then evaluated immunohistochemically and subsequently correlated with the corresponding clinicopathological parameters. RESULTS: Head and neck cancer cells cultured in arginine-free medium either completely stopped proliferating, or proliferated minimally. In addition, ADI treatment inhibited the growth of all 8 head and neck cancer cell lines to different degrees. Although cellular ASS level did not correlate well with ADI-sensitivity among these cell lines, knockdown of endogenous ASS potentiated the growth-inhibitory effect of ADI in each individual cell line (FaDu and OEC-M1). In multivariable analysis, high tumor ASS level independently predicted an unfavorable disease-free survival in OSCC patients. CONCLUSION: High tumor ASS status is an independent variable predicting a poor disease-free survival in OSCC patients. Arginine deprivation therapy may potentially be used as a new approach to treat head and neck cancer.
OBJECTIVES:Arginine is a nonessential amino acid which can regulate tumor growth. Argininosuccinate synthetase (ASS) is the rate-limiting enzyme for de novo arginine production. The expression pattern of ASS and the feasibility of arginine deprivation therapy in head and neck cancer have not been investigated. MATERIALS AND METHODS: The growth-inhibitory effect of arginine deprivation therapy was assessed either by proliferation assay with head and neck cancer cells cultured in arginine-free medium, or by tetrazolium/formazan dye assay with cells treated with an arginine-depleting drug (arginine deiminase, ADI). The tumorASS status of 73 oral squamous carcinoma (OSCC) patients was then evaluated immunohistochemically and subsequently correlated with the corresponding clinicopathological parameters. RESULTS: Head and neck cancer cells cultured in arginine-free medium either completely stopped proliferating, or proliferated minimally. In addition, ADI treatment inhibited the growth of all 8 head and neck cancer cell lines to different degrees. Although cellular ASS level did not correlate well with ADI-sensitivity among these cell lines, knockdown of endogenous ASS potentiated the growth-inhibitory effect of ADI in each individual cell line (FaDu and OEC-M1). In multivariable analysis, high tumorASS level independently predicted an unfavorable disease-free survival in OSCC patients. CONCLUSION: High tumorASS status is an independent variable predicting a poor disease-free survival in OSCC patients. Arginine deprivation therapy may potentially be used as a new approach to treat head and neck cancer.
Authors: Chun A Changou; Yun-Ru Chen; Li Xing; Yun Yen; Frank Y S Chuang; R Holland Cheng; Richard J Bold; David K Ann; Hsing-Jien Kung Journal: Proc Natl Acad Sci U S A Date: 2014-08-13 Impact factor: 11.205
Authors: Fuming Qiu; Yun-Ru Chen; Xiyong Liu; Cheng-Ying Chu; Li-Jiuan Shen; Jinghong Xu; Shikha Gaur; Henry Jay Forman; Hang Zhang; Shu Zheng; Yun Yen; Jian Huang; Hsing-Jien Kung; David K Ann Journal: Sci Signal Date: 2014-04-01 Impact factor: 8.192
Authors: Katie Meehan; Connull Leslie; Michaela Lucas; Angela Jacques; Bob Mirzai; James Lim; Max Bulsara; Yasir Khan; Nicholas C Wong; Benjamin Solomon; Chady Sader; Peter Friedland; Gisela Mir Arnau; Timothy Semple; Annette M Lim Journal: Cancer Med Date: 2020-05-08 Impact factor: 4.452
Authors: Leanne Lee Leung; Nicolas Cheuk Hang Lau; Jiaxun Liu; Xinyu Qu; Stephen Kwok-Wing Tsui; Jinpao Hou; Cherie Tsz-Yiu Law; Tung Him Ng; Judy Wai Ping Yam; Chit Chow; Amy B W Chan; Jason Y K Chan; Katie Meehan Journal: Cancers (Basel) Date: 2021-12-01 Impact factor: 6.639